Evidence map›Paper›PMID 40334085›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2025

PGI2 restricts trained ILC2 responses in allergic inflammation.

Weisong Zhou, Jian Zhang, Allison E Norlander, Daniel P Cook, Shinji Toki, Masako Abney, Mark Rusznak, Christopher Thomas, Christian Warren, Bradley W Richmond and 4 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Group 2 innate lymphoid cells: Where are we 15 years out?The Journal of allergy and clinical immunology · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Weisong ZhouDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States.
Jian ZhangDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States.
Allison E NorlanderDepartment of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, United States.ORCID 0000-0002-9357-485X
Daniel P CookDepartment of Internal Medicine, University of Iowa, Iowa City, IA, United States.ORCID 0000-0002-1152-4454
Shinji TokiDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States.
Masako AbneyDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States.
Mark RusznakDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States.
Christopher ThomasDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States.
Christian WarrenVA Tennessee Valley Health Care System, U.S. Department of Veterans Affairs, Nashville, TN, United States.
Bradley W RichmondDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States.ORCID 0000-0001-6200-5235
Katherine Gibson-CorleyDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, United States.ORCID 0000-0002-1846-1580
Ginger L MilneDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States.
Dawn C NewcombDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States.
R Stokes PeeblesDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States.ORCID 0000-0002-1429-7875

Funding

Viral and Host Determinants of Infant and Childhood Allergy and AsthmaU19AI095227 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Dawn C Newcomb · 2011 to 2026
$34.9M
PGI2 augments Treg functionR01AI145265 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PEEBLES, RAY STOKES · 2019 to 2023
$2.7M
GLP-1R signaling in allergic inflammationR01AI124456 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI NISWENDER, KEVIN D, PEEBLES, RAY STOKES · 2017 to 2021
$2.2M
PGI2 regulation of TSLP-mediated allergic inflammation in the lungR01AI111820 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PEEBLES, RAY STOKES · 2014 to 2018
$2.0M
Host genetics of allergen-induced lung TSLP expression and ILC2 functionR21AI145397 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PEEBLES, RAY STOKES · 2019 to 2020
$468k
BLRD VA I01 BX004299Department of Veterans Affairs Biomedical Laboratory Research and Development Service 101BX004299NIAID NIH HHS R01 AI111820NIAID NIH HHS R01 AI124456NIAID NIH HHS R01 AI145265NIAID NIH HHS R21 AI145397NIAID NIH HHS U19 AI095227NIH HHS R01AI111820NIH HHS R01 AI124456NIH HHS R01 AI145265NIH HHS R21 AI145397NIH HHS U19 AI095227U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development Service 101BX004299
6 · The paper itself

Abstract

Pulmonary type 2 innate lymphoid cells (ILC2s) exhibit immune memory, termed "trained immunity," which enhances their activation following exposure to an independent protease-containing allergen. The role of prostaglandin I2 (PGI2), a cyclooxygenase (COX) pathway metabolite, in modulating these trained ILC2 responses remains unclear. PGI2 acts through its G protein-coupled receptor IP. We hypothesized that IP signaling inhibits ILC2 training. To test this hypothesis, we used a mouse ILC2 training model in which we challenged wild-type (WT) and IP knockout (KO) mice with Alternaria alternata extract (Alt) to induce ILC2 activation and training. After a 33-d resting period, ILC2 responses subsided to a homeostatic level. Mice were then intranasally challenged with papain to evaluate responses to an unrelated allergen. IP KO mice displayed significantly heightened ILC2 interleukin (IL)-13 expression and with concomitant increased eosinophilia in the lungs post-papain challenge compared with WT control mice. Notably, neither WT nor IP KO mice challenged with papain only, devoid of ILC2 training, exhibited lung type 2 responses. The augmented type 2 inflammation observed in IP KO mice following both Alt and papain challenges correlated with increased numbers and percentages of IL-13-producing ILC2s and greater mean fluorescence intensity of IL-13 compared with WT mice. Furthermore, RNA sequencing of sorted ILC2s from WT and IP KO mice following Alt-papain challenges revealed heightened activation of immune response pathways and mitochondrial respiratory pathways in IP-deficient ILC2s. These findings reveal an inhibitory role of PGI2 signaling in trained ILC2 responses, emphasizing its pivotal contribution to innate immune responses and allergic inflammation.

Indexed as

EpoprostenolHypersensitivityInflammationLymphocytesAllergensAlternariaAnimalsImmunity, InnateImmunologic MemoryInterleukin-13LungMiceMice, Inbred C57BLMice, KnockoutPapainAllergensEpoprostenolInterleukin-13PapainILC2inflammationlungmouse

Identifiers

PMID40334085
PMCPMC12311380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.